3PD - ALK and MET are synergistic co-activators of downstream signals by amplification in pulmonary sarcomatoid carcinoma: a potential for targeted therapy?
|Date||27 March 2014|
|Session||Poster Discussion 1|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
P. Gasparini1, G. Pelosi2, G. Sozzi3, V. Ciravolo3, S. Pupa3, E. Tamborini2, P. Scanagatta4, F. De Braud5, U. Pastorino4
Genetic alterations suitable for targeted therapy are poorly known issues in pulmonary sarcomatoid carcinoma (PSC), an uncommon and life-threatening family of non-small cell lung cancer (NSCLC). We here investigate the role of ALK and MET in this subtype of aggressive NSCLC.